Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression

Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression

Background The immunotherapy targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death ligand-1 (PD-L1) has achieved significant breakthroughs, but further improvements are still needed in cancer treatment.Methods We investigated orlistat, a drug approved by the Food a...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Li, Shiming Yang, Liting Wang, Xiaoyan Zhao, Changjiang Hu, Qingyun Tang, Lianhua Zhang, Shuo Zeng, Qiyu Bao, Weichao Hu, Lijiao He, Guiping Huang, Yunyi Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2025-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/3/e008923.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://jitc.bmj.com/content/13/3/e008923.full

Similar Items